Patents by Inventor Amir Ashoorzadeh
Amir Ashoorzadeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11661404Abstract: AKR1C3-activated prodrugs of Formula (I), pharmaceutical compositions comprising prodrugs of Formula (I), and their use in the treatment of hyperproliferative diseases such as cancer and for cell ablation. The compounds of the invention are able to penetrate neoplasm tissue and be selectively reduced to an active (cytotoxic) form by contact with an AKR1C3 enzyme found in the neoplasm. This active form is therefore able to ablate AKR1C3-expressing target cells of the neoplasm and therefore has particular utility in the treatment of cancer and other hyperproliferative disorders.Type: GrantFiled: March 25, 2019Date of Patent: May 30, 2023Assignee: ACHILLES MEDICAL LIMITEDInventors: Amir Ashoorzadeh, Christopher Paul Guise, Adam Vorn Patterson, Jeffrey Bruce Smaill
-
Patent number: 11192890Abstract: Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.Type: GrantFiled: March 2, 2018Date of Patent: December 7, 2021Assignees: AUCKLAND UNISERVICES LIMITED, GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTHInventors: Adam Vorn Patterson, Jeffrey Bruce Smaill, Amir Ashoorzadeh, Christopher Paul Guise, Christopher John Squire, Swarnalatha Akuratiya Gamage, Maria Rosaria Abbattista, Matthew Roy Bull, Angus Cheverton Grey, Xueqiang Li, Ke Ding, Xiaomei Ren, Shuang Jiang, Zhengchao Tu
-
Publication number: 20210196681Abstract: The present invention relates to selective presenilin-2 ?-secretase inhibitors for use in the treatment of various diseases associated with a defect leading to Notch receptor hyperactivity. In particular the present invention relates to selective presenilin-2 ?-secretase inhibitors for use as a highly selective anti-cancer treatment. Preferred selective presenilin-2 ?-secretase inhibitors include small molecules, like 4-aminoquinolines or imidazole compounds, (monoclonal) antibodies and known ?-secretase inhibitors or analogues and combinations thereof.Type: ApplicationFiled: August 27, 2019Publication date: July 1, 2021Inventors: Marc Antoine Gijbert Gilles Vooijs, Adrianus Johannes Groot, Jeffrey Bruce Smaill, Patrick David O'Connor, Amir Ashoorzadeh
-
Publication number: 20210115002Abstract: AKR1C3-activated prodrugs of Formula (I), pharmaceutical compositions comprising prodrugs of Formula (I), and their use in the treatment of hyperproliferative diseases such as cancer and for cell ablation. The compounds of the invention are able to penetrate neoplasm tissue and be selectively reduced to an active (cytotoxic) form by contact with an AKR1C3 enzyme found in the neoplasm. This active form is therefore able to ablate AKR1C3-expressing target cells of the neoplasm and therefore has particular utility in the treatment of cancer and other hyperproliferative disorders.Type: ApplicationFiled: March 25, 2019Publication date: April 22, 2021Inventors: Amir ASHOORZADEH, Christopher Paul GUISE, Adam Vorn PATTERSON, Jeffrey Bruce SMALL
-
Publication number: 20200017491Abstract: Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.Type: ApplicationFiled: March 2, 2018Publication date: January 16, 2020Applicants: Auckland Uniservices Limited, Guangzhou Intitute of BioMedicine and HealthInventors: Adam Vorn PATTERSON, Jeffrey Bruce SMAILL, Amir ASHOORZADEH, Christopher Paul GUISE, Christopher John SQUIRE, Swarnalatha Akuratiya GAMAGE, Maria Rosaria ABBATTISTA, Matthew Roy BULL, Angus Cheverton GREY, Xueqiang LI, Ke DING, Xiaomei REN, Shuang JIANG, Zhengchao TU
-
Patent number: 10357577Abstract: The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: more particularly, although not exclusively, the enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.Type: GrantFiled: July 18, 2011Date of Patent: July 23, 2019Assignees: AUCKLAND UNISERVICES LIMITED, VICTORIA LINK LIMITEDInventors: Christopher Paul Guise, David Francis Ackerley, Amir Ashoorzadeh, Janine Naomi Copp, Jack Urquhart Flanagan, Alexandra Marie Mowday, Adam Vorn Patterson, Gareth Adrian Prosser, Jeffrey Bruce Smaill, Sophie Phillipa Syddall, Elsie May Williams
-
Publication number: 20190153002Abstract: The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.Type: ApplicationFiled: January 18, 2019Publication date: May 23, 2019Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Amir Ashoorzadeh, Christopher Paul Guise, Alexandra Marie Mowday, David Francis Ackerley, Elsie May Williams, Janine Naomi Copp
-
Patent number: 10202408Abstract: The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.Type: GrantFiled: January 22, 2018Date of Patent: February 12, 2019Assignee: Health Innovation Ventures B.V.Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Amir Ashoorzadeh, Christopher Paul Guise, Alexandra Marie Mowday, David Francis Ackerley, Elsie May Williams, Janine Naomi Copp
-
Publication number: 20180148463Abstract: The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.Type: ApplicationFiled: January 22, 2018Publication date: May 31, 2018Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Amir Ashoorzadeh, Christopher Paul Guise, Alexandra Marie Mowday, David Francis Ackerley, Elsie May Williams, Janine Naomi Copp
-
Patent number: 9873710Abstract: The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.Type: GrantFiled: October 31, 2016Date of Patent: January 23, 2018Assignee: Health Innovation Ventures B.V.Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Amir Ashoorzadeh, Christopher Paul Guise, Alexandra Marie Mowday, David Francis Ackerley, Elsie May Williams, Janine Naomi Copp
-
Publication number: 20170044191Abstract: The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.Type: ApplicationFiled: October 31, 2016Publication date: February 16, 2017Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Amir Ashoorzadeh, Christopher Paul Guise, Alexandra Marie Mowday, David Francis Ackerley, Elsie May Williams, Janine Naomi Copp
-
Patent number: 9505791Abstract: The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.Type: GrantFiled: August 22, 2013Date of Patent: November 29, 2016Assignee: Health Innovation Ventures B.V.Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Amir Ashoorzadeh, Christopher Paul Guise, Alexandra Marie Mowday, David Francis Ackerley, Elsie May Williams, Janine Naomi Copp
-
Publication number: 20160031877Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy- and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R3 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R2 is in the 3-position in combination with R3 in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R3 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso thatType: ApplicationFiled: June 30, 2015Publication date: February 4, 2016Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
-
Publication number: 20160002222Abstract: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocyde or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3, and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.Type: ApplicationFiled: June 4, 2015Publication date: January 7, 2016Inventors: Jeffrey Bruce Smaill, ADAM VORN PATTERSON, MICHAEL PATRICK HAY, WILLIAM ALEXANDER DENNY, WILLIAM ROBERT WILSON, GUO-LIANG LU, ROBERT FORBES ANDERSON, HO HUAT LEE, AMIR ASHOORZADEH
-
Publication number: 20150299230Abstract: The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.Type: ApplicationFiled: August 22, 2013Publication date: October 22, 2015Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Amir Ashoorzadeh, Christopher Paul Guise, Alexandra Marie Mowday, David Francis Ackerley, Elsie May Williams, Janine Naomi Copp
-
Patent number: 9101632Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy-and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R1 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R1 is in the 3-position in combination with R3, in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R1 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso thatType: GrantFiled: September 2, 2010Date of Patent: August 11, 2015Assignee: AUCKLAND UNISERVICES LIMITEDInventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling Annie Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
-
Patent number: 9073916Abstract: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.Type: GrantFiled: March 11, 2010Date of Patent: July 7, 2015Assignee: AUCKLAND UNISERVICES LIMITEDInventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Michael Patrick Hay, William Alexander Denny, William Robert Wilson, Guo-Liang Lu, Robert Forbes Anderson, Ho Huat Lee, Amir Ashoorzadeh
-
Publication number: 20150010474Abstract: The invention relates generally to compounds and methods for imaging and/or selective ablation of nitroreductase-expressing cells and/or biological agents. More particularly, although not exclusively, the invention provides compounds that are selectively metabolised by bacterial nitroreductases and are substantially insensitive to metabolism under oxic or hypoxic conditions by human nitroreductase enzymes.Type: ApplicationFiled: December 21, 2012Publication date: January 8, 2015Inventors: Robert Forbes Anderson, Jeffery Bruce Smaill, Adam Vorn Patterson, Amir Ashoorzadeh, David Francis Ackerley, Janine Naomi Copp, Alexandra Marie Mowday, Elsie May Williams, Christopher Paul Guise, Cameron Koch, Alex Kachur, William R. Dolbier, JR.
-
Publication number: 20130295011Abstract: The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: More particularly, although not exclusively, said enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.Type: ApplicationFiled: July 18, 2011Publication date: November 7, 2013Applicants: VICTORIA LINK LIMITED, AUCKLAND UNISERVICES LIMITEDInventors: Christopher Paul Guise, David Francis Ackerley, Amir Ashoorzadeh, Janine Naomi Copp, Jack Urquhart Flanagan, Alexandra Marie Mowday, Adam Vorn Patterson, Gareth Adrian Prosser, Jeffrey Bruce Smaill, Sophie Phillipa Syddall, Elsie May Williams
-
Publication number: 20120202832Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy- and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R1 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R1 is in the 3-position in combination with R3, in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R1 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso thaType: ApplicationFiled: September 2, 2010Publication date: August 9, 2012Applicant: Auckland Uniservices LimitedInventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling (Annie) Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin